Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Bacteraemia Treated with Tigecycline Monotherapy-Validation of 2019's EUCAST Proposed Breakpoint Changes

• Main Authors: Matthaios Papadimitriou-Olivgeris (Author), Christina Bartzavali (Author), Alexandra Nikolopoulou (Author), Fevronia Kolonitsiou (Author), Virginia Mplani (Author), Iris Spiliopoulou (Author), Myrto Christofidou (Author), Fotini Fligou (Author), Markos Marangos (Author)
• Format: Book
• Published: MDPI AG, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Tigecycline is a therapeutic option for carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp). Our aim was to evaluate the impact of the tigecycline's minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline...